期刊文献+

胰腺癌的治疗靶点 被引量:1

Therapeutic Targets of Pancreatic Cancer
原文传递
导出
摘要 目的总结胰腺癌(PC)的治疗靶点。方法采用文献复习的方法,对关于PC治疗靶点的文献加以综述。结果 PC是目前世界上最具挑战性的肿瘤之一,其进展性很强,预后很差,死亡率很高。PC的一个治疗难点就是它对放化疗不敏感,目前的化疗方案还不能明显改善患者的生存期。最近,一些新的治疗方案可以改善PC患者的预后,涉及到信号传导通路、免疫反应、基质反应和表观遗传变异。结论在PC的治疗中涉及多种治疗靶点。鉴于当前的治疗方案不能显著阻止PC的进展和改善其生存期,未来对于新治疗方案和临床研究的需求必将越来越强烈。 Objective To summarize the therapeutic targets of pancreatic cancer(PC). Methods The related literatures about the therapeutic targets of PC were reviewed. Results PC was one of the most challenging tumor in worldwide, and was characterized as a highly aggressive disease with poor overall prognosis and a high mortality rate. The hallmark of PC was its poor response to radio- and chemo-therapy. Current chemotherapeutic regimens could not provide substantial survival benefit with a clear increase in overall survival. Recently, several new approaches which could significantly improve the clinical outcome of PC had been described, involving signal-transduction pathways, immune response, stroma reaction, and epigenetic changes. Conclusions Many therapeutic targets are involved in the treatment of PC. As current therapies failed to significantly improve the progression and the survival of PC, new therapeutic approaches and clinical studies are strongly required.
出处 《中国普外基础与临床杂志》 CAS 2015年第3期369-374,共6页 Chinese Journal of Bases and Clinics In General Surgery
关键词 胰腺癌 治疗靶点 信号传导通路 免疫反应 基质反应 表观遗传变异 Pancreatic cancer Therapeutic targets Signal-transduction pathways Immune response Stroma reaction Epigenetic changes
  • 相关文献

参考文献2

二级参考文献21

  • 1Natalia JURA,Herbert ARCHER,Dafna BAR-SAGI.Chronic pancreatitis,pancreatic adenocarcinoma and the black box in-between[J].Cell Research,2005,15(1):72-77. 被引量:13
  • 2Aranda E,Manzano JL,Rivera F,Galán M,Valladares- Ayerbes M,Pericay C,Safont MJ,Mendez MJ,Irigoyen A,Arrivi A,Sastre J,Díaz-Rubio E.Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: rela- tionship between skin rash and survival (Pantar study)[].Annals of Oncology.2012
  • 3Klapdor R,Klapdor S,Bahlo M.Combination therapy w ith gemcitabine (GEM)and erlotinib (E)in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9[].Anticancer Research.2012
  • 4CARNEIRO BA,BRAND RE,FINE E,et al.Phase I trial of fixeddose rate infusion gemcitabine with gefitinib in patients with pan-creatic carcinoma[].Cancer Investigation.2007
  • 5RP A’Hern.Sample size tables for exact single-stage phase II designs[].Statistics in Medicine.2001
  • 6Conroy T,Desseigne F,Ychou M,BouchéO,Guimbaud R,Bécouarn Y,Adenis A,Raoul JL,Gourgou-Bourgade S,de la Fouchardière C,Bennouna J,Bachet JB,Khemissa-Akouz F,Péré-VergéD,Delbaldo C,Assenat E,Chauffert B,Michel P,Montoto-Grillot C,Ducreux M.FOLFIRINOX versus gem- citabine for metastatic pancreatic cancer[].The New England Journal of Medicine.2011
  • 7Tempero M,Plunkett W,Ruiz Van Haperen V,et al.Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma[].Journal of Clinical Oncology.2003
  • 8Kaplan EL,Meier P.Nonparametric estimation from incomplete observations[].Journal of the American Statistical Association.1958
  • 9Cox DR.Regression models and life tables (with discussion)[].Journal of the Royal Statistical Society Series B Statistical Methodology.1972
  • 10Halm U,Schumann T,Schiefke I,et al.Decrease of CA19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer[].British Journal of Cancer.2000

共引文献18

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部